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Overview. Head and neck cancers (HNC) are a heterogeneous group of tumors that arise from the squamous epithelium. Surgery
and radiation therapy are standard treatments in most cases. Transoral laser microsurgery (TLM) offers new perspectives for
organ preservation in the surgical treatment of these patients.
Objetive. To analyze the overall survival (OS), disease-free survival (DFS) at 10 years and type of recurrence in patients treated
with (TLM) and radiotherapy of HNC.
Methods. This retrospective study was based on a review of medical records from 80 patients with HNC, diagnosed at Donostia
Hospital, San Sebastián, Spain, between January, 2000 and June, 2011. Medical records were provided by the Otorhinolaryngology
and Radiation Oncology departments. All medical records were analyzed for the following clinical variables: sex, age, tumor site,
histopathology, type of adjuvant therapy, TNM and stage, OS, DFS and type of recurrence.
Results. 75 males and 5 females were included. Median age was 63 (44–83) years old. 76.3% of tumors were located in supraglottis;
57.5% moderately differentiated; 80% T2 and T3; 31% N0, 18.8% N1 and 25.1% N2; 35.5% corresponded to stage III and 51.3% to
stage IV; extracapsular extension was found in 27.5%. All patients were treated with TLM and radiotherapy; lymphadenectomy
was made in 86.3%, chemotherapy was administered in 38.8%. Local recurrence was 15% and regional recurrence 13.8% at 10
years. OS was 75% and 46.6% at 5 and 10 years; DFS was 88% and 85.1% at 5 and 10 years.
Conclusions. Our data show that TLM followed by adjuvant radiotherapy provides excellent results for patients with HNC and can
be therefore an option instead of more aggressive treatments.
http://dx.doi.org/10.1016/j.rpor.2013.03.282
Role of 18FDG-PET/CT for radiotherapy planning in head and neck cancer
N. Farré1, L. Díez1, J. Rojas1, J. de Vega1, A. Latorre-musoll 2, A. Fernández3, V. Camacho3, K. Majercakova1,
P. Buitrago1, D. Giménez1, X. León4, A. López-pousa5, J. Craven-bartle1
1 Fund. Gest. San. Hosp. Sta. Creu I St. Pau, Oncología Radioterápica
2 Fund. Gest. San. Hosp. Sta. Creu I St. Pau, Radiofísica y Radioprotección
3 Fund. Gest. San. Hosp. Sta. Creu I St. Pau, Medicina Nuclear
4 Fund. Gest. San. Hosp. Sta. Creu I St. Pau, Otorrinolaringología
5 Fund. Gest. San. Hosp. Sta. Creu I St. Pau, Oncología Médica
Introduction. In head and neck cancer, 18FDG-PET/CT appears to be more sensitive than traditional CT-MRI-based delineation to
deﬁne volumes for planning radiotherapy.
Purpose. The aim of this study was to analyze the outcome of using a single 18FDG-PET/CT procedure for staging, planning and
contouring volumes for patients with head and neck cancer.
Methods and materials. In 2012, 22 patients with stage II–IV squamous cell carcinoma of head and neck underwent an 18FDG-
PET/CT in treatment position (with thermoplastic mask) for staging and planning purposes. 17/22 patients undergoing radical
radiotherapy were included. 18FDG-PET/CT studies were transferred to Eclipse (Varian Medical Systems) treatment planning
system. GTV were delineated using CT information only (GTVCT), and with SUV thresholds of 20, 30 and 40% of the maximum
PET uptake. We then integrated both CT and PET information (GTVplan), for T and N volumes.
Results. Staging was modiﬁed in 5 of the 22 patients (23%), due to overstaging in 4 patients and understaging in 1. For the
17 selected patients, GTVplan volume decreased 0–10% compared to GTVCT in 13.3% of cases and 10–50% in 6.7%. GTVplan
volume increased 0–10% in 46.7% of cases, 10–30% in 20%, and 30–70% in 13.4%. Pearson correlation index for T volumes between
GTVplan-T and GTVPET-T (threshold of 20–30–40%) was 0.74–0.85–0.84, respectively. Pearson correlation index for N volumes
between GTVplan-N and GTVPET-N was 0.41.
Conclusions. 18FDG-PET/CT improves patient selection for radical treatment and provides useful information for radiation treat-
ment planning in head and neck cancer. Using 18FDG-PET/CT imaging for staging and planning, does not increase the workload
and it is cost-effective in the patients selected for RT.
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